Le syndrome de Lynch est responsable d’environ 5% des cas de cancer colorectaux (CCR). Il correspond à la transmission d’une mutation,variation génétique rare, qui confère un haut risque de CCR. Une telle mutationn’est cependant identifiée que dans une famille sur deux. Dans lesfamilles sans mutation identifiée, dites négatives, le risque de CCR est malconnu en particulier les estimations individuelles du risque. Cette thèse comportedeux objectifs principaux. Obj. 1- étudier les stratégies capables de réduireles tailles d’échantillon dans les études visant à identifier de nouveauxgènes de susceptibilité ; et Obj. 2- définir un cadre théorique permettantd’estimer des risques individualisés de CCR dans les familles négatives, enutilisant l’histoire familiale et personnelle de CCR de l’individu. Notre travails’appuie sur la théorie des modèles mendéliens et la simulation de donnéesfamiliales, à partir desquelles il est possible d’étudier la puissance d’étudesd’identification, et d’évaluer in silico les qualités prédictives de méthodesd’estimation du risque. Les résultats obtenus apportent des connaissancesnouvelles pour la planification d’études futures. D’autre part, la cadre méthodologiqueque nous proposons permet une estimation plus précise durisque individuel, permettant d’envisager une surveillance plus individualisée. / Lynch syndrome is responsible of about 5% of cases of colorectal cancer (CRC). It corresponds to the transmission of a mutation, which is arare genetic variant, that confers a high risk of CRC. Such a mutation isidentified, however, in only one family of two. In families without identifiedmutation, called negative, the risk of CRC is largely unknown in particularthere is a lack of individualized risk estimates. This thesis has two main objectives.Obj. 1 - to explore strategies that could reduce the required samplesizes of identification studies, and Obj. 2 - to define a theoretical frameworkfor estimating individualized risk of CRC in negative families, using personaland family history of CRC of the individuals. Our work is based on thetheory of Mendelian models and the simulation of family data, from whichit is possible to study the power of identification studies as well as to assessand compare in silico the predictive ability of risk estimation methods. Theresults provide new knowledge for designing future studies, and the methodologicalframework we propose allows a more precise estimate of risk, thatmight lead to a more individualized cancer follow-up.

Les lymphocytes T ?d seraient des effecteurs essentiels dans la réponse immunitaire aux stress induits notamment par les infections et la tumorigénèse. Plusieurs arguments dont leur localisation intra-épithéliale mais aussi leurs capacités effectrices multiples et rapides les caractérisent comme des acteurs primordiaux dans l’immunité anti-tumorale. Mon projet de thèse consistait à examiner le potentiel anti-tumoral des lymphocytes T ?d humains, Vd2 négatifs (neg), dans un contexte in vivo, grâce à l’utilisation d’un modèle murin. Des études antérieures menées au laboratoire démontraient une expansion de lymphocytes T Vd2neg dans la circulation sanguine de transplantés rénaux développant une infection à cytomégalovirus (CMV). Des clones T Vd2neg, isolés de ces patients, présentaient une forte réactivité in vitro contre des cellules infectées par le CMV mais aussi contre des cellules tumorales notamment d’origine colique (comme la lignée HT29). Un ligand commun induit par l’infection à CMV et la transformation tumorale, reconnu par les clones T Vd2neg serait à l’origine de cette double réactivité. La première partie de mon projet s’est concentrée sur l’étude du potentiel anti-tumoral de ces clones T Vd2neg in vivo, qui comprenait leur capacité à atteindre des cellules tumorales d’origines coliques (HT29) et à les lyser. Dans un modèle de xénogreffe dans des souris immunodéficientes, nous avons démontré que les clones TVd2neg, injectés dans le péritoine (i.p) pouvaient retarder la croissance de tumeurs solides HT29 sous-cutanées. D’après nos résultats, cette inhibition du développement tumoral proviendrait d’une action précoce et spécifique des cellules T Vd2neg et impliquerait le récepteur à chimiokine CCR3. Nos données suggèrent donc que des lymphocytes T Vd2neg, réactifs contre le CMV, pourraient migrer in vivo jusqu’au site d’injection des cellules tumorales et inhiber la croissance de la tumeur probablement grâce à leur acticité cytolytique. La deuxième partie de mon projet de thèse proposait d’approfondir l’étude du rôle des lymphocytes T Vd2neg contre les tumeurs coliques. Ainsi nous avons testé, in vivo, l’implication de lymphocytes T Vd1+ humains, une population représentative des épithéliums intestinaux, dans le cancer métastatique colorectal (CMC). Nous avons développé un modèle d’implantation orthotopique de cellules tumorales HT29 dans des souris immunodéficientes, qui mime le développement du CMC chez l’homme. Des tumeurs primaires intra-caecales et des métastases pulmonaires et hépatiques se développent chez les souris. De plus, nous avons pu suivre leur croissance grâce à l’introduction de la luciférase dans les HT29 et à une technique d’imagerie in vivo en bioluminescence. Nos résultats montrent qu’un traitement continu des souris par des injections de lignée T Vd1+ en i.p inhibe le développement des tumeurs primaires et retarde l’apparition des métastases à distance. Ces données soutiennent l’implication des lymphocytes T Vd2neg dans le contrôle des CMC. De façon intéressante, elles mettent en avant une implication anti-métastatique des cellules T Vd2neg. L’ensemble de nos travaux souligne le rôle des cellules T Vd2neg dans la réponse immunitaire contre les cancers colorectaux et étaye leur potentiel d’action lors de la progression des tumeurs vers des métastases, ouvrant ainsi des perspectives pour l’utilisation de ces cellules dans les thérapies des CMC. / Gamma delta (?d) T lymphocytes contribute to host immune competence uniquely especially during stress immune responses to infections and tumors. Because ?d T cells colonize epithelial surfaces, where they can exert rapid and pleiotropic effector functions, they are critical protagonists in anti-cancer response. During my Phd project we explored the anti-tumor potential of Vd2 negatives (neg) ?d T lymphocytes, in vivo using a mouse xenograft tumor model. A few years ago, studies in our laboratory showed an increase of peripheral blood Vd2neg ?d T lymphocytes in allograft recipients infected by cytomegalovirus (CMV). Interestingly, Vd2neg ?d T clones isolated from these patients showed a cytotoxic activity against CMV infected fibroblast in vitro. Moreover, they were able to kill colon cancer cells (HT29) in vitro, in contrast to normal epithelial cells. Cancer cell- as well as CMV infected cell- killing involved T cell receptor (TCR) engagement, independently of major histocompatibility complex (CMH) recognition, probably with a common ligand. The first part of my Phd project was undertaken to evaluate the in vivo tumor reactivity of anti-CMV Vd2neg clones, including their ability to inhibit tumor growth as well as their migratory potential toward colon cancer cells. In immunodeficient mice, we showed that systemic intraperitoneal (i.p) injections with human Vd2neg clones inhibited the growth of HT29 hypodermal tumors xenografts. Furthermore, our results demonstrated that Vd2neg T cells had an early and specific anti-tumor effect, and that such activity could be hampered in vivo using an anti-CCR3 antibody. Our study suggest that Vd2neg T cells with an anti-viral potential are able to reach a tumor site in vivo, and inhibit tumoral growth exercising a cytolytic activity. The second part of my Phd project proposed to get further insights on the role of Vd2neg T cells in the immune surveillance against colon cancer. To this aim, we tested, the involvement of human Vd1+ T lymphocytes, a substantial fraction of T cells in intestinal epithelia, in limiting tumor spread in vivo, using a mouse model of colorectal carcinoma (CRC). We sat up a physiological mouse model of CRC by orthotopic microinjection of HT29 colon cell, which mimics the natural history of human CRC. Indeed, primary colic tumors and pulmonary and hepatic distant metastases grew in mice. Furthermore, bioluminescence imaging was used to follow the outcome of luciferase expressing cancer cells. We showed that systemic treatment with human Vd1+ T lymphocytes could inhibit the growth of intracaecal HT29 tumors and led a substantial reduction of distant metastases. Our results are the first arguing for a crucial role of ?d T cells against CRC, specially in preventing the dissemination of colon cancer cells. Taken together, our results underline the role of of ?d T cells in theimmune response against colorectal cancer. Our findings put forward Vd2neg T cells as attractive candidates for novel anti-tumor immunotherapy protocols.

Le cetuximab est une thérapie ciblée dirigée contre le récepteur du facteur de croissance épidermique (EGFR) utilisée dans le cancer colorectal (CCR) en combinaison avec des chimiothérapies (5-FU, irinotécan et oxaliplatine). Sa fixation inhibe les voies de signalisation en aval du récepteur conduisant à une diminution de la prolifération et de la survie des cellules ciblées. Cependant, chez les patients atteint de CCR présentant une protéine KRAS mutée, le cetuximab est inefficace, de plus, la moitié des patients présentant une protéine KRAS wild-type ne répond pas non plus au cetuximab. Afin de découvrir des nouveaux biomarqueurs de sélection des patients qui pourraient bénéficier de ce traitement ou d'améliorer la réponse des patients, une meilleure connaissance des mécanismes d'action du cetuximab est nécessaire. Par exemple récemment, des études ont montré que la protéine p53 participait à la réponse au cetuximab. Il serait intéressant de savoir si le statut de cette protéine peut constituer un bon marqueur de réponse. Précédemment, nous avons montré que l'activation de la « mitogen activated protein kinase » p38 (MAPK p38) induit une résistance à l'irinotécan in vitro et in vivo et est un marqueur de non réponse à cette drogue. De plus, d'autres équipes ont montré que la MAPK p38 bloque également la réponse au 5-FU et participe à la cytotoxicité de l'oxaliplatine. Il semble alors que la MAPK p38 soit impliquée dans les mécanismes d'action des anti-tumoraux. Il est donc intéressant de savoir si la MAPK p38 participe également à la cytotoxicité des thérapies ciblées comme le cetuximab. Pour répondre à ces questions nous avons choisi de comparer deux lignées cellulaires de CCR KRAS wild-type mais au statut TP53 différent et qui répondent différemment au cetuximab: la lignée Caco2 (30% d'inhibition de la survie, TP53 muté) et la lignée DiFi (80% d'inhibition de la survie, TP53 sauvage). Nous avons effectué des tests de cytotoxicité combinant le cetuximab et l'inhibition transcriptionnelle ou pharmacologique de p38 ou l'inhibition transcriptionnelle de p53. Nous avons également testé l'apoptose et la prolifération induite par le cetuximab en l'absence de la MAPK p38 ou de p53. Enfin nous avons testé l'expression des gènes BIM, p27 et PUMA impliqués dans l'apoptose et la prolifération. Dans cette étude, nous avons démontré que la MAPK p38 et p53 participent à l'effet cytotoxique du cetuximab dans les cellules DiFi. En revanche, dans les cellules Caco2, la MAPK p38 bloque partiellement l'effet du cetuximab. Nous avons également montré l'implication de p38 et p53 dans l'apoptose induite par le cetuximab et l'implication de p38 dans l'inhibition de la prolifération. La protéine p38 est impliquée dans la régulation de ERK et dans la localisation nucléaire de FOXO3a responsable de l'expression des gènes BIM et p27. Enfin, nous avons montré que p38 a également un rôle dans le mécanisme d'action d'inhibiteurs de tyrosine kinase ciblant l'EGFR (lapatinib et erlotinib). Pour conclure, nous avons déterminé que p38 et p53 sont impliquées dans le mécanisme d'action du cetuximab. Nous avons décris l'implication de la voie p38-FOXO3a dans le mécanisme d'action du cetuximab. Enfin, p38 et p53 semblent être de bons biomarqueurs de réponse au cetuximab. / Cetuximab is used in colorectal cancer (CRC), as targeted therapy against the Epithelial Growth Factor receptor (EGFR), in association with chemotherapy (5-FU, oxaliplatin and irinotecan). Its binding inhibits signaling pathways downstream to the receptor leading to a decrease in proliferation and surviving. In KRAS mutated CRC patients, Cetuximab is ineffective, and half of KRAS Wild Type (WT) patients does not respond to Cetuximab either. Thus, a better knowledge of Cetuximab mechanism of action will help to improve response rate and to find new biomarkers of response. Recently, studies have shown that p53 protein is involved in the response to cetuximab. It would be interesting to know if the status of this protein could be a biomarker of response. Previously, we have shown that activation of the mitogen activated protein kinase p38 (p38MAPK) induces irinotecan resistance in vitro and in vivo and is a predictive factor of response to irinotecan. Moreover, others teams found that p38 MAPK also partially block 5-FU response and participate to oxaliplatin cytotoxicity. It seems that p38 is involved in mechanism of action of anti-tumor agent. The aim of our project is to determine, in KRAS WT colorectal cells, if p38 MAPK is involved as well in the cetuximab effect. In this aim, experiments were done on two KRAS WT CRC cell lines but with different p53 status which respond differently to Cetuximab: Caco2 cells (30% of survival inhibition, TP53 mutated) and DiFi cells (80% of survival inhibition, TP53 wild-type). Cytotoxic experiments combining cetuximab treatment and inhibition of p38MAPK or p53 by transcriptional inhibition or using a pharmacological inhibitor of p38 (SB202190) were performed. We assessed apoptosis and inhibition of proliferation by FACS analysis of cell cycle and DNA synthesis. In addition, BIM, PUMA and p27 expression were analyzed by QPCR and Western Blot. Our results showed that inhibition of p38MAPK enhances Cetuximab cytotoxic effect in Caco2 cells but impairs it in DiFi cells as inhibition of p53. We also observed that inhibition of p38 MAPK and p53 decreases cetuximab induced apoptosis and inhibition of p38 decrease anti-proliferative effect in DiFi cells. The prevention of cell death by SB202190 in cetuximab treated DiFi cells could be explained by ERK pathway activation and the decrease of FOXO3a nuclear localization leading to p27 and BIM expression decrease, respectively involved in cellular proliferation and mitochondrial apoptosis. Our results have shown the same inhibiting effect of SB202190 on the cytotoxic effect of two tyrosine-kinase inhibitors targeting EGFR (lapatinib and erlotinib) in DiFi cells indicating that p38MAPK implication is linked to inhibition of EGFR kinase activity not to Cetuximab only. We have shown that p38MAPK is involved in response to the inhibition of EGFR activity via nuclear localization of FOXO3a. p53 protein has also a role in cetuximab response. Both seem to be predictive factors of response to cetuximab therapy.

La sénescence induite par chimiothérapie permet l’arrêt pérenne de la division des cellules tumorales. Néanmoins, ce mécanisme de suppression tumorale peut être neutralisé par certaines cellules traitées, ce qui se traduit généralement par une rechute des patients. Récemment, nous avons décrit dans des cellules colorectales un mécanisme d’échappement à la sénescence induite par le SN-38 dépendant de la protéine de survie MCL1. Cette étude montre que les cellules sénescentes (PLS) favorisent la prolifération des cellules non-sénescentes (PLD) par l’intermédiaire de signaux mitogéniques activant la kinase Cdk4 et par conséquent la reprise de la division. Nous démontrons que Cdk4 inhibe Rb par phosphorylation de la sérine 780, permettant l’activation des fonctions transcriptionnelles des facteurs E2F sur les gènes du cycle cellulaire. La perte d’activité de Cdk4 par ARN interférence ou par le Palbociclib réduit l’émergence de clones proliférants. La méthyltransférase EZH2 est une cible de E2F exclusivement exprimée par les PLD et son expression dépend de l’activité de Cdk4. Par ailleurs, l’utilisation d’ARN interférence dirigé contre EZH2 ou des inhibiteurs chimiques DNZepA et GSK343 réduit également l’émergence de clones proliférants. Enfin, son inhibition potentialise à la fois l’arrêt de la division et la sénescence en réponse au Palbociclib dans les cellules ayant échappé au SN-38. Ainsi, ces travaux ont permis de mettre en évidence un rôle important de EZH2 en tant qu’effecteur de Cdk4 dans le mécanisme d’échappement au SN-38, une voie susceptible d’apporter des nouvelles cibles thérapeutiques dans le traitement du cancer. / Chemotherapy-induced senescence enables to trigger a durable division arrest of tumor cells. However, this tumor suppressor mechanism is neutralized in some treated cells leading mostly to cancer relapse in patients. Recently, we have described a MCL1-dependent mechanism of escape in SN-38-induced senescence from colorectal cell lines. In this study, we showed that senescent cells (PLS cells) promoted the non senescent cells (PLD cells) proliferation through mitogenic signals stimulating Cdk4 kinase activity and subsequently the cell cycle. We demonstrated that Cdk4 phosphorylated Rb on the serine 780 to inhibit its activity, allowing E2F- family transcriptional functions activation on cell cycle targets. Loss of Cdk4 expression or activity induced by RNA interference or Palbociclib reduced the emergence of proliferating clones. TheEZH2-methyltransferase, a E2F transcriptional target, is only expressed by PLD cells and this expression depends on Cdk4 activity. Moreover, loss of EZH2 expression or activity, by RNA interference or by DZNepA and GSK343 inhibitors, reduced the emergence of proliferating cells. Finally, EZH2 inhibition promotes both cell division arrest and senescence in response to Palbociclibin the SN-38-escaped cells. To conclude, this study enabled to highlight a major role of EZH2 as effector of Cdk4 in the escape mechanism induced by SN-38 a signaling pathway offering newtargeted cancer therapies.

No description available.

O câncer colorretal (CCR) é o terceiro tipo de câncer mais comum no mundo. Apesar dos avanços nos tratamentos convencionais, aproximadamente dois terços dos pacientes com CCR são submetidos à cirurgia potencialmente curativa. Entretanto, grande parte desses pacientes evolui mal, apresentando recidivas e/ou metástases. A busca de novos alvos moleculares para a terapia do CCR revelou a proteína celular Prion (PrPC) como um possível candidato. Trabalhos recentes sugerem participação direta ou indireta de PrPC no crescimento de tumores, na formação de metástases, na composição de complexos multiproteicos e na indução de vias de sinalização envolvidas em diversos processos biológicos, como proliferação. Além disso, PrPC foi descrito como um importante modulador do crescimento de tumor colorretal. Resultados prévios mostraram que a interação da proteína PrPC com a proteína HSP70/HSP90 Organizing Protein (HOP) induz proliferação em glioblastomas. HOP é uma proteína predominantemente citoplasmática, podendo também ser secretada associada às vesículas extracelulares. Assim, o presente estudo objetivou avaliar o papel do complexo PrPC-HOP e das vesículas extracelulares no desenvolvimento e progressão dos tumores colorretais. Os nossos resultados mostram que HOP induziu migração e invasão em linhagens de CCR de maneira dependente de PrPC, uma vez que o uso do peptídeo sem atividade que compete pelo sítio ligação de HOP a PrPC inibiu estes processos. Além disso, nossos dados apontaram que o aumento de migração e invasão das células de CCR induzida pela interação PrPC-HOP é mediada pela ativação da via ERK1/2. Os achados in vitro estimularam a avaliação do perfil de expressão de PrPC e HOP por imuno-histoquímica em tecidos de pacientes com diferentes tipos de tumores colorretais. Nossos resultados sugeriram que essas proteínas são importantes no início do desenvolvimento tumoral e na transição de adenomas para adenocarcinomas, não havendo correlação entre a presença de HOP e/ou PrPC com metástase, linfonodos acometidos, estadiamento, sobrevida ou região tumoral versus tecido normal. Em relação ao papel das vesículas extracelulares na progressão dos tumores colorretais, nossos resultados mostraram que linhagens celulares que apresentam padrões parecidos de agressividade tumoral podem ter perfis de secreção de proteínas e vesículas extracelulares bastante diferentes, induzindo, portanto, processos biológicos com intensidades distintas. O meio condicionado e as vesículas extracelulares da linhagem WiDr apresentaram maior potencial de indução de migração quando comparado com a linhagem HCT8. Além disso, a modulação negativa da proteína VPS4, uma das responsáveis pela formação dos corpos multivesiculares, mostrou-se uma abordagem interessante no estudo da secreção de vesículas por células de CCR, uma vez que o dominante negativo de VPS4 promoveu diminuição do cargo proteico e da secreção de vesículas extracelulares, redução da proliferação celular e do efeito indutor do processo de migração na linhagem WiDr. Assim, em conjunto, o presente trabalho indicou que o complexo PrPC-HOP pode ser um bom alvo terapêutico nos processos de migração e invasão em CCR. Ainda, essas proteínas se mostraram importantes nos estágios iniciais da formação dos tumores. A modulação da secreção de vesículas extracelulares pode contribuir para retardar a progressão dos tumores colorretais. / Colorectal cancer (CRC) is the third most common type of cancer in the world. Despite improvements in conventional treatments, approximately two-thirds of CRC patients undergo potentially curative surgery. However, most of these patients evolve poorly, showing recurrence and/or metastasis. Search of new molecular targets for CRC therapy revealed the cellular protein Prion (PrPC) as a putative candidate. Recent studies have shown that PrPC exhibit direct or indirect participation in tumor growth, formation of metastasis, composition of multiprotein complexes and induction of signaling pathways involved in many biological processes such as proliferation. Moreover, PrPC has been described as an important modulator of colorectal tumor growth. Previous findings showed that the interaction between PrPC and its ligand HSP70/90 heat shock organizing protein (HOP) induces gliobastoma proliferation. It is well known that HOP localizes mainly in the cytoplasm but HOP is also secreted associated with extracellular vesicles. In this way, the present study sought to evaluate the role of PrPC-HOP complex and extracellular vesicles in the development and progression of CRC. We demonstrate that HOP induces the migration and invasion of CRC cell lines in a PrPC-dependent manner because the use of HOP peptide, which is able to bind to PrPC, blocking PrPC-HOP complex formation, inhibited the migration and invasion processes. In addition, our data showed that the enhancement of migration and invasion induced by PrPC-HOP interaction is mediated by ERK1/2 pathway activation. These in vitro results lead us to evaluate the PrPC and HOP expression by immunohistochemistry in tissues from patients with different tumor types. Our data showed that these proteins could be important for the initial steps of tumor development, represented by the transition from adenoma to adenocarcinoma. No correlation was found among HOP and/or PrPC expression and metastasis, lymph node involvement, staging, survival or tumor area versus normal tissue. Regarding the role of extracellular vesicles in the progression of colorectal tumors, our results showed that cell lines exhibiting similar aggressive tumor behavior can have a different protein secretion pattern and a distinct profile of extracellular vesicles release, which could induce biological process with different intensities. The conditioned medium and the extracellular vesicles derived from WiDr cell line showed a higher potential to induce migration than HCT8 cell line. Moreover, the negative modulation of VPS4, one of the proteins responsible for multivesicular body formation, showed to be an interesting approach in the study of extracellular vesicles secretion secreted by CRC cells; the negative dominant of VPS4 promoted in the WiDr cell line a reduction in the protein cargo and secretion of the extracellular vesicles, a decrease of cell proliferation and induction of migration process. Therefore, taken together, our data highlights that PrPC-HOP complex can be considered a new therapeutic target in migration and invasion processes of CRC. Moreover, these proteins appeared to be important at onset of tumor formation. The modulation of extracellular vesicles secretion may contribute for delaying the progression of colorectal tumors.

En France, en 2012, les sujets âgés d’au moins 65 ans représentaient 71 % de l’incidence du Cancer ColoRectal (CCR). Depuis 2005, des thérapies ciblées ont été autorisées dans le CCR métastatique (CCRm) et sont recommandées en 1ère ligne en association à une chimiothérapie. Face à un manque d’évaluation de ces médicaments chez le sujet âgé, l’objectif de ce travail était l’étude, en situation réelle de soins, de l’utilisation, des bénéfices et de la sécurité d'emploi des médicaments anticancéreux, dont les thérapies ciblées, chez le sujet âgé et/ou fragile atteint de CCRm. Une revue systématique de la littérature a confirmé la faible inclusion des sujets âgés et fragiles dans les essais cliniques évaluant les thérapies ciblées dans le CCRm. D’après une étude sur des données mondiales de pharmacovigilance et la réunion de deux cohortes de terrain de patients traités par thérapies ciblées, nous avons montré que leur effectivité et sécurité d’emploi chez le sujet âgé étaient équivalentes à celles du sujet plus jeune. Dans la cohorte, la fragilité vis-à-vis des effets indésirables graves et du décès était liée aux caractéristiques du CCRm. Enfin, d’après une étude de terrain pilote et une cohorte dans les données de l’Assurance Maladie française, nous avons montré que, chez le sujet âgé, le traitement par médicaments anticancéreux, dont les thérapies ciblées, n’était pas optimal et encore très lié à l’âge des patients. Le rapport bénéfices/risques des thérapies ciblées semble donc positif dans la population âgée atteinte de CCRm actuellement traitée. Cependant, la population âgée traitée ne semble pas encore totalement correspondre à celle qui pourrait bénéficier du traitement. / In France, in 2012, patients aged at least 65 years accounted for 71% of the incidence of ColoRectal Cancer (CCR). Since 2005, targeted therapies have been authorized in metastatic CRC (mCRC) and are recommended in first-line in combination with conventional chemotherapy. Given this lack of evaluation of these drugs in the elderly, the objective of this work was the study, in real-life setting, of the use, the benefits and the safety of anticancer drugs, including targeted therapies in elderly and/or frail mCRC patients. A systematic review of the literature confirmed the low inclusion of elderly and frail patients in clinical trials evaluating targeted therapies in the mCRC. According to a study on international pharmacovigilance data and the pooling of two field cohorts of patients treated by targeted therapies, we showed that their effectiveness and safety in the elderly were equivalent to those of the younger. In the cohort, frailty regarding serious adverse events and death was related to the characteristics of the mCRC. Finally, according to a pilot field study and a cohort in the French health insurance data, we have shown that, in the elderly, the treatment with anticancer drugs, including targeted therapies, was not optimal and still very related to the age of the patients. The benefit/risk ratio of targeted therapies therefore seems positive in the elderly population with mCRC currently treated. However, the elderly population treated does not seem to be fully matching with those who would benefit from treatment.

De par leur incidence et un diagnostic tardif, les cancers du sein et du colon restent parmi les plus meurtriers en France. L’identification de marqueur précoce semble primordiale pour détecter rapidement ces maladies et ainsi améliorer la survie des patients. Le protéome de chaque stade du cancer du côlon a été identifié et quantifié par spectrométrie de masse. L’Olfactomedine-4 (OLFM4) a été définie comme un biomarqueur potentiel par sa présence dans le sérum et ses variations d’expression. Alors que cette protéine est surexprimée, au niveau du site tumoral primaire,uniquement dans les stades précoces du cancer colorectal, sa surexpression est maintenue dans le sang des patients tous stades confondus. Cette variabilité d’expression est également retrouvée dans le cancer du sein. L’OLFM4 est décrite comme un marqueur des cellules souches colorectales mais ses fonctions restent contradictoires. Selon le contexte cellulaire, nos travaux associent cette protéine sécrétée à l’établissement de propriétés de cellule souche cancéreuse comme la prolifération en faible adhésion et la formation de mammosphères. Elle facilite également le processus migratoire et la résistance à la chimiothérapie. De plus, des expériences in vivo ont confirmé le caractère protumoral de cette protéine. Nous avons également mis en évidence son implication dans la régulation de l’expression du facteur de transcription GLI1 de la voie Sonic Hedgehog et de protéines d’adhésion telle que l’E-Cadherine. Cette étude décrit le lien étroit entre l’induction d’un phénotype agressif et l’OLFM4 dont le dosage sérique permettrait une détection précoce de ces maladies. / Through their high frequencies and the lack of early diagnosis, breast and colorectal cancer remain poor prognosis’ diseases. Therefor, the identification of early markers appears as crucial. The proteomic approach isone of the potential tools to identify these biomarkers as it enables the study of tumour cell lines or tissues amples. Indeed, proteins enriched from a shotgun proteomic approach can be identified and quantified by mass spectrometry. In a previous study, we have analysed the proteome of colorectal tumour at different stages and defined Olfactomedine-4 (OLFM4) as a potential biomarker. While OLFM4 expression is increased at primary tumoral site only in non-invasive stages, we have observed that OLFM4 isover expressed in the blood of patients regardless of the cancer stage. The same analysis was made on breast cancer patients. Although OLFM4 has been described as a stem cell marker, its functions remain unclear. In this study, we found that OLFM4 confers cancer stem cell properties. It acts as a regulator of proliferation in low adhesion conditions, migration, mammosphere formation and tumor growth. These abilities could be dependent of Sonic Hedgehog signalling pathway, especially of transcriptional factor GLI1, and regulation of adhesion proteins like E-cadherin. According to the cellular background, all these features highlight a close relationship between a potential biomarker and its involvement in the acquisition of an aggressive phenotype.

O câncer colorretal (CCR) é o terceiro tipo de câncer mais comum no mundo. Apesar dos avanços nos tratamentos convencionais, aproximadamente dois terços dos pacientes com CCR são submetidos à cirurgia potencialmente curativa. Entretanto, grande parte desses pacientes evolui mal, apresentando recidivas e/ou metástases. A busca de novos alvos moleculares para a terapia do CCR revelou a proteína celular Prion (PrPC) como um possível candidato. Trabalhos recentes sugerem participação direta ou indireta de PrPC no crescimento de tumores, na formação de metástases, na composição de complexos multiproteicos e na indução de vias de sinalização envolvidas em diversos processos biológicos, como proliferação. Além disso, PrPC foi descrito como um importante modulador do crescimento de tumor colorretal. Resultados prévios mostraram que a interação da proteína PrPC com a proteína HSP70/HSP90 Organizing Protein (HOP) induz proliferação em glioblastomas. HOP é uma proteína predominantemente citoplasmática, podendo também ser secretada associada às vesículas extracelulares. Assim, o presente estudo objetivou avaliar o papel do complexo PrPC-HOP e das vesículas extracelulares no desenvolvimento e progressão dos tumores colorretais. Os nossos resultados mostram que HOP induziu migração e invasão em linhagens de CCR de maneira dependente de PrPC, uma vez que o uso do peptídeo sem atividade que compete pelo sítio ligação de HOP a PrPC inibiu estes processos. Além disso, nossos dados apontaram que o aumento de migração e invasão das células de CCR induzida pela interação PrPC-HOP é mediada pela ativação da via ERK1/2. Os achados in vitro estimularam a avaliação do perfil de expressão de PrPC e HOP por imuno-histoquímica em tecidos de pacientes com diferentes tipos de tumores colorretais. Nossos resultados sugeriram que essas proteínas são importantes no início do desenvolvimento tumoral e na transição de adenomas para adenocarcinomas, não havendo correlação entre a presença de HOP e/ou PrPC com metástase, linfonodos acometidos, estadiamento, sobrevida ou região tumoral versus tecido normal. Em relação ao papel das vesículas extracelulares na progressão dos tumores colorretais, nossos resultados mostraram que linhagens celulares que apresentam padrões parecidos de agressividade tumoral podem ter perfis de secreção de proteínas e vesículas extracelulares bastante diferentes, induzindo, portanto, processos biológicos com intensidades distintas. O meio condicionado e as vesículas extracelulares da linhagem WiDr apresentaram maior potencial de indução de migração quando comparado com a linhagem HCT8. Além disso, a modulação negativa da proteína VPS4, uma das responsáveis pela formação dos corpos multivesiculares, mostrou-se uma abordagem interessante no estudo da secreção de vesículas por células de CCR, uma vez que o dominante negativo de VPS4 promoveu diminuição do cargo proteico e da secreção de vesículas extracelulares, redução da proliferação celular e do efeito indutor do processo de migração na linhagem WiDr. Assim, em conjunto, o presente trabalho indicou que o complexo PrPC-HOP pode ser um bom alvo terapêutico nos processos de migração e invasão em CCR. Ainda, essas proteínas se mostraram importantes nos estágios iniciais da formação dos tumores. A modulação da secreção de vesículas extracelulares pode contribuir para retardar a progressão dos tumores colorretais. / Colorectal cancer (CRC) is the third most common type of cancer in the world. Despite improvements in conventional treatments, approximately two-thirds of CRC patients undergo potentially curative surgery. However, most of these patients evolve poorly, showing recurrence and/or metastasis. Search of new molecular targets for CRC therapy revealed the cellular protein Prion (PrPC) as a putative candidate. Recent studies have shown that PrPC exhibit direct or indirect participation in tumor growth, formation of metastasis, composition of multiprotein complexes and induction of signaling pathways involved in many biological processes such as proliferation. Moreover, PrPC has been described as an important modulator of colorectal tumor growth. Previous findings showed that the interaction between PrPC and its ligand HSP70/90 heat shock organizing protein (HOP) induces gliobastoma proliferation. It is well known that HOP localizes mainly in the cytoplasm but HOP is also secreted associated with extracellular vesicles. In this way, the present study sought to evaluate the role of PrPC-HOP complex and extracellular vesicles in the development and progression of CRC. We demonstrate that HOP induces the migration and invasion of CRC cell lines in a PrPC-dependent manner because the use of HOP peptide, which is able to bind to PrPC, blocking PrPC-HOP complex formation, inhibited the migration and invasion processes. In addition, our data showed that the enhancement of migration and invasion induced by PrPC-HOP interaction is mediated by ERK1/2 pathway activation. These in vitro results lead us to evaluate the PrPC and HOP expression by immunohistochemistry in tissues from patients with different tumor types. Our data showed that these proteins could be important for the initial steps of tumor development, represented by the transition from adenoma to adenocarcinoma. No correlation was found among HOP and/or PrPC expression and metastasis, lymph node involvement, staging, survival or tumor area versus normal tissue. Regarding the role of extracellular vesicles in the progression of colorectal tumors, our results showed that cell lines exhibiting similar aggressive tumor behavior can have a different protein secretion pattern and a distinct profile of extracellular vesicles release, which could induce biological process with different intensities. The conditioned medium and the extracellular vesicles derived from WiDr cell line showed a higher potential to induce migration than HCT8 cell line. Moreover, the negative modulation of VPS4, one of the proteins responsible for multivesicular body formation, showed to be an interesting approach in the study of extracellular vesicles secretion secreted by CRC cells; the negative dominant of VPS4 promoted in the WiDr cell line a reduction in the protein cargo and secretion of the extracellular vesicles, a decrease of cell proliferation and induction of migration process. Therefore, taken together, our data highlights that PrPC-HOP complex can be considered a new therapeutic target in migration and invasion processes of CRC. Moreover, these proteins appeared to be important at onset of tumor formation. The modulation of extracellular vesicles secretion may contribute for delaying the progression of colorectal tumors.

The human microbiome - defined as the microbial communities that live in and on our bodies - is emerging as a key factor in human diseases. The expanding research field that investigates the role of the microbiome on human cancer development, termed oncobiome, has led to important discoveries such as the role of Fusobacterium nucleatum in colorectal cancer carcinogenesis and tumor progression. Motivated by these discoveries, this thesis studied the oncobiome from different perspectives, investigating whether alterations to microbial profiles were associated with disease status or an adverse response to treatment. We used both biopsy tissue samples and 16S rRNA amplicon sequencing (N = 36), as well as privately and publicly available fecal whole metagenomes (N = 764) to investigate microbiome-colorectal cancer (CRC) associations. We observed significant increases in species richness in CRC, regardless of sample type or methodology, which was partially due to expansions of species typically from the oral cavity, as well as an overabundance of specific taxa such as Bacteroides fragilis, Fusobacterium, Desulfovibrio and Bilophila in CRC. Functional potential analysis of CRC metagenomes revealed that the choline trimethylamine-lyase (cutC) gene was over-abundant in CRC, with the strength of association dependent on four identified sequence variants, pointing at a novel potential mechanism of CRC carcinogenesis. Predictive microbiome signatures trained on the combination of multiple datasets showed very high and consistent performances on distinct cohorts (average AUC 0.83, minimum 0.81). To investigate the microbiomes role in response to treatment, we profiled microbial communities of gastric wash samples in gastric cancer patients (N = 36) before and after neoadjuvant chemotherapy through 16S rRNA amplicon sequencing. Gastric wash microbial communities presented remarkably high inter-individual variation, with significant decreases in richness and phylogenetic diversity after treatment and associations with pH, pathological response and sample collection. The most abundant genera found in patients before or after chemotherapy treatment included Streptococcus, Prevotella, Rothia and Veillonella. Despite limitations inherent to differing experimental choices, this thesis provides microbiome signatures that can be the basis for clinical prognostic tests and hypothesis-driven mechanistic studies, as well as supporting the role of the human oral microbiome in whole-body diseases. / O microbioma humano - definido como as comunidades microbianas que vivem sobre e dentro do corpo humano - está se tornando um fator cada vez mais importante em doenças humanas. O campo de estudo que investiga o papel do microbioma no desenvolvimento do câncer humano, denominado oncobioma, está crescendo e já levou a importantes descobertas como o papel da espécie Fusobacterium nucleatum na carcinogênese e progressão tumoral de tumores colorretais. Motivado por estas descobertas, esta tese de doutorado analisou o oncobioma por diferentes perspectivas, investigando se alterações nos perfis microbianos estavam associados à presença da doença ou a uma resposta adversa ao tratamento. Usamos tanto amostras de tecidos de biópsias e o sequenciamento do gene 16S rRNA (N = 36), quanto metagenomas fecais públicos e privados (N = 764), para investigar associações entre o microbioma e o câncer colorretal (CCR). Observamos um aumento significativo da riqueza microbiana no CCR, independentemente do tipo da amostra ou metodologia, que era em parte, devido ao aumento de espécies tipicamente presentes na cavidade oral. Observamos também um aumento da abundância de táxons específicos no CCR, que incluíam Bacteroides fragilis, Fusobacterium, Desulfovibrio e Bilophila. Analisando o potencial funcional dos metagenomas, encontramos um aumento significativo da enzima liase colina trimetilamina (cutC) no CCR, cuja associação era dependente de 4 variantes de sequência, demonstrando ser um possível novo mecanismo de carcinogênese no CCR. Assinaturas preditivas do microbioma treinadas na combinação dos estudos demonstraram ser altamente preditivas e consistentes nos diferentes estudos (média de AUC 0.83, mínimo de 0.81). Para investigar o possível papel do microbioma na resposta ao tratamento, analisamos os perfis microbianos do suco gástrico de pacientes com câncer gástrico (N = 36) antes e depois do tratamento quimioterápico neoadjuvante. As comunidades microbianas apresentaram uma variabilidade inter-individual notavelmente grande, com diminuições significativas na riqueza e diversidade filogenética pós tratamento, além de estarem associadas principalmente ao pH, mas também à resposta patológica e ao tempo da coleta. Os gêneros mais abundantes encontrados nos pacientes antes ou depois da quimioterapia incluíam Streptococcus, Prevotella, Rothia e Veillonella. Apesar das limitações inerentes às escolhas experimentais, esta tese proporciona assinaturas do microbioma que podem servir de base para testes clínicos prognósticos e estudos mecanísticos, além de dar mais suporte ao papel do microbioma oral em doenças humanas.